Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Total Enrollment
1458 participants
Study Classification
OBSERVATIONAL
Study Start Date
2022-06-23
Study Completion Date
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Tuberculosis (TB) is the biggest infectious cause of death worldwide, and the biggest cause of death in Sub-Saharan Africa among HIV-positive patients. There is need for a non-sputum-based rapid triage test that identifies individuals with presumptive TB requiring confirmatory diagnostic investigation. Such a test could reduce the burden on health systems, expedite referral and confirmatory testing, and treatment thereby reducing transmission.
A non-sputum triage test is needed as many symptomatic patients including those with HIV, can often not produce high quality sputum (which most current diagnostics rely on). Several blood transcriptional diagnostic signatures produced due to immune responses to M. tuberculosis infection have previously been described, however there is lack of real-world performance data especially in high TB/HIV-endemic African settings where rates of HIV (that could compromise sensitivity) and previous TB (that could compromise specificity) are high. Furthermore, by building on prior research that used untargeted sequencing approaches to identify candidate signatures, the investigators are now at a stage to perform the targeted signature measurement at a large scale and cost-efficient manner as part of prospective diagnostic accuracy analyses in real-world settings.
Using the framework provided by ongoing funded diagnostic clinical trials with similar eligibility criteria, in presumptive TB participants (≥18 years) who visit selected health facilities in Cape Town, South Africa, RADIANT has a unique opportunity to pursue several important research questions. RADIANT aims are to 1) evaluate the sensitivity and specificity of selected concise peripheral host transcriptional signatures for active TB among symptomatic persons in South Africa; 2) design a cost-optimised diagnostic algorithm based on transcriptional signatures, SeroSelectTB (an EDCTP funded pan-African evaluation of a point-of-care serological triage test for active TB) results, and confirmatory bacteriological testing, and 3) characterise bacteriologically-negative patients classified as non-TB to determine if those with elevated host transcriptional signatures have other respiratory pathogens (detected in nasopharyngeal swabs using a commercial multiplex panel) and/or develop active TB within six months (incident active TB).
A non-sputum triage test is needed as many symptomatic patients including those with HIV, can often not produce high quality sputum (which most current diagnostics rely on). Several blood transcriptional diagnostic signatures produced due to immune responses to M. tuberculosis infection have previously been described, however there is lack of real-world performance data especially in high TB/HIV-endemic African settings where rates of HIV (that could compromise sensitivity) and previous TB (that could compromise specificity) are high. Furthermore, by building on prior research that used untargeted sequencing approaches to identify candidate signatures, the investigators are now at a stage to perform the targeted signature measurement at a large scale and cost-efficient manner as part of prospective diagnostic accuracy analyses in real-world settings.
Using the framework provided by ongoing funded diagnostic clinical trials with similar eligibility criteria, in presumptive TB participants (≥18 years) who visit selected health facilities in Cape Town, South Africa, RADIANT has a unique opportunity to pursue several important research questions. RADIANT aims are to 1) evaluate the sensitivity and specificity of selected concise peripheral host transcriptional signatures for active TB among symptomatic persons in South Africa; 2) design a cost-optimised diagnostic algorithm based on transcriptional signatures, SeroSelectTB (an EDCTP funded pan-African evaluation of a point-of-care serological triage test for active TB) results, and confirmatory bacteriological testing, and 3) characterise bacteriologically-negative patients classified as non-TB to determine if those with elevated host transcriptional signatures have other respiratory pathogens (detected in nasopharyngeal swabs using a commercial multiplex panel) and/or develop active TB within six months (incident active TB).
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Timely and correct diagnosis of TB is vital for control of the global TB epidemic. TB screening for passive case-finding relies on symptoms, and its limited by its suboptimal sensitivity, hence there is need for a rapid triage test that identifies symptomatic individuals prior to confirmatory diagnostic investigation. Such a test could reduce the burden on health systems and patients, and expedite referral, confirmatory testing, and treatment. Generally, suitable non-sputum tests are not available, and this is primarily because of a lack of biomarkers. A non-sputum-based triage test is required as many people with TB, including those co-infected with HIV and those with incipient early disease, can often not produce high quality sputum, which most current diagnostics (sputum-based smear microscopy, Mycobacteria Growth Indicator Tube (MGIT) 960 liquid culture, and molecular detection by Xpert MTB/RIF (Xpert) or Xpert MTB/RIF Ultra (Ultra)) rely on.
In patients undergoing pulmonary and/or extrapulmonary TB assessments, a diagnostic test based on blood biomarkers would be optimal, as blood is easily obtainable. Several blood transcriptional diagnostic signatures have previously been described, and these biomarkers hold the most promise in the near future for meeting World Health Organization triage test target product profile criteria. There, however, is lack of real-world prospective performance data especially in high TB/HIV-endemic African settings.
One recent study, which used patients recruited by the group in which this proposal is based, provided the first prospective, systematic head-to-head comparison of the diagnostic accuracy of 27 blood transcriptional signatures for active TB identified through a previous systematic review. This study allowed concise signatures to be identified with Sweeney3, Kaforou25, Roe3 and BATF2 signatures having the highest diagnostic accuracy. This study, however, is limited in its sample size and did not comprehensively characterise patients without TB who had a positive signature score. Therefore, further large-scale, prospective validation studies to compare multiple transcriptional signatures in real-world settings, are important to advance transcriptional signatures through the diagnostics pipeline. Put simply, test developers need to know which, of the signatures that are now available and relatively concise, hold the most promise.
Importantly, these signatures are reflective of the inflammatory state of the host. Furthermore, patients who have elevated signatures but are culture-negative may have sub-clinical incipient TB, in that they will shortly become culture-positive and develop incident active TB. In other words, in such a situation, the signatures could have prospective predictive value and enable clinics to detect patients before they represent a significant infectious risk. As blood transcriptional changes may predate microbiological confirmation, delay in starting treatment pending microbiological culture leads to increased risk of MTB transmission. A study that included longitudinal sampling of HIV-negative adolescents with latent TB revealed that blood transcriptional signatures could detect subclinical incipient disease up to 12 months before a conventional clinical diagnosis was made.
Also, patients who are signature positive but do not have active TB (classically defined culture-positive sputum) are still sick and require characterisation. This could inform future algorithms that investigate such patients. Therefore, the investigators will apply a next-generation sequencing -based respiratory pathogen panel to characterize respiratory pathogens.
As high costs could be a limitation to the implementation of transcriptional signatures as a test for active TB in resource-constrained settings, a strategy to select patients with increased probability of having TB, to get screened by RNA-based triage test before confirmatory testing may result in a more affordable diagnostic algorithm, and improve the cost-effectiveness of RNA-based TB test. The investigators will explore combinations of sensitivity, and specificity of each pre-defined transcriptional signature with other TB tests, including the novel SeroSelectTB blood triage test, to detect which optimal test combinations will improve affordability of the RNA-based assay. A previous study had earlier employed this strategy for the optimal use of the Xpert test.
This proposal therefore aims to evaluate the diagnostic accuracy of selected host transcriptional signatures in the blood of symptomatic participants seeking care at selected health facilities in Cape Town, South Africa, and characterise bacteriologically negative patients classified as non-TB to determine if elevated host transcriptional signatures are associated with other respiratory pathogens (detected in nasopharyngeal swabs using a commercial multiplex panel) or can predict active TB within six months (incident active TB).
The investigators will use, as a scaffold, ongoing funded diagnostic clinical trials with similar eligibility criteria and recruiting participants (≥18 years) with respiratory symptoms who visit selected health facilities in Cape Town, South Africa, to collect Tempus Blood RNA and nasopharyngeal swab specimen at baseline, and longitudinally, in a subset of people.
The study's hypotheses are 1) selected blood transcriptional signatures have a high diagnostic accuracy, defined as minimum of 90% sensitivity and 70% specificity for WHO target product profile for a triage test, when compared to a microbiological reference standard; 2) In bacteriologically negative patients classified as non-TB, baseline host transcriptional signatures can predict active TB within six months (incident TB); (3) respiratory pathogens other than TB in patients bacteriologically negative for TB are associated with elevated transcriptional signatures.
Ultimately, RADIANT aims to show that blood transcriptional signatures can be used as a triage test for TB or as an add-on confirmatory TB test, and characterisation of respiratory tract pathogens has the potential to direct appropriate therapy and infection control precautions.
In patients undergoing pulmonary and/or extrapulmonary TB assessments, a diagnostic test based on blood biomarkers would be optimal, as blood is easily obtainable. Several blood transcriptional diagnostic signatures have previously been described, and these biomarkers hold the most promise in the near future for meeting World Health Organization triage test target product profile criteria. There, however, is lack of real-world prospective performance data especially in high TB/HIV-endemic African settings.
One recent study, which used patients recruited by the group in which this proposal is based, provided the first prospective, systematic head-to-head comparison of the diagnostic accuracy of 27 blood transcriptional signatures for active TB identified through a previous systematic review. This study allowed concise signatures to be identified with Sweeney3, Kaforou25, Roe3 and BATF2 signatures having the highest diagnostic accuracy. This study, however, is limited in its sample size and did not comprehensively characterise patients without TB who had a positive signature score. Therefore, further large-scale, prospective validation studies to compare multiple transcriptional signatures in real-world settings, are important to advance transcriptional signatures through the diagnostics pipeline. Put simply, test developers need to know which, of the signatures that are now available and relatively concise, hold the most promise.
Importantly, these signatures are reflective of the inflammatory state of the host. Furthermore, patients who have elevated signatures but are culture-negative may have sub-clinical incipient TB, in that they will shortly become culture-positive and develop incident active TB. In other words, in such a situation, the signatures could have prospective predictive value and enable clinics to detect patients before they represent a significant infectious risk. As blood transcriptional changes may predate microbiological confirmation, delay in starting treatment pending microbiological culture leads to increased risk of MTB transmission. A study that included longitudinal sampling of HIV-negative adolescents with latent TB revealed that blood transcriptional signatures could detect subclinical incipient disease up to 12 months before a conventional clinical diagnosis was made.
Also, patients who are signature positive but do not have active TB (classically defined culture-positive sputum) are still sick and require characterisation. This could inform future algorithms that investigate such patients. Therefore, the investigators will apply a next-generation sequencing -based respiratory pathogen panel to characterize respiratory pathogens.
As high costs could be a limitation to the implementation of transcriptional signatures as a test for active TB in resource-constrained settings, a strategy to select patients with increased probability of having TB, to get screened by RNA-based triage test before confirmatory testing may result in a more affordable diagnostic algorithm, and improve the cost-effectiveness of RNA-based TB test. The investigators will explore combinations of sensitivity, and specificity of each pre-defined transcriptional signature with other TB tests, including the novel SeroSelectTB blood triage test, to detect which optimal test combinations will improve affordability of the RNA-based assay. A previous study had earlier employed this strategy for the optimal use of the Xpert test.
This proposal therefore aims to evaluate the diagnostic accuracy of selected host transcriptional signatures in the blood of symptomatic participants seeking care at selected health facilities in Cape Town, South Africa, and characterise bacteriologically negative patients classified as non-TB to determine if elevated host transcriptional signatures are associated with other respiratory pathogens (detected in nasopharyngeal swabs using a commercial multiplex panel) or can predict active TB within six months (incident active TB).
The investigators will use, as a scaffold, ongoing funded diagnostic clinical trials with similar eligibility criteria and recruiting participants (≥18 years) with respiratory symptoms who visit selected health facilities in Cape Town, South Africa, to collect Tempus Blood RNA and nasopharyngeal swab specimen at baseline, and longitudinally, in a subset of people.
The study's hypotheses are 1) selected blood transcriptional signatures have a high diagnostic accuracy, defined as minimum of 90% sensitivity and 70% specificity for WHO target product profile for a triage test, when compared to a microbiological reference standard; 2) In bacteriologically negative patients classified as non-TB, baseline host transcriptional signatures can predict active TB within six months (incident TB); (3) respiratory pathogens other than TB in patients bacteriologically negative for TB are associated with elevated transcriptional signatures.
Ultimately, RADIANT aims to show that blood transcriptional signatures can be used as a triage test for TB or as an add-on confirmatory TB test, and characterisation of respiratory tract pathogens has the potential to direct appropriate therapy and infection control precautions.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Tuberculosis
Lower Respiratory Infection
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Diagnostics
Triage
Transcriptional profiling
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adults aged 18 years and above
* Signed written informed consent or witnessed oral consent in case of illiteracy, before undertaking any study-related activities
* Are unwell and are suspected to have tuberculosis
* Signed written informed consent or witnessed oral consent in case of illiteracy, before undertaking any study-related activities
* Are unwell and are suspected to have tuberculosis
Exclusion Criteria
* Currently receiving TB treatment
* In the past 3 months, participants have been on TB treatment for 30 or more days
* In the past 3 months, participants have been on TB treatment for 30 or more days
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European and Developing Countries Clinical Trials Partnership (EDCTP)
OTHER_GOV
Sponsor Role
collaborator
University of Stellenbosch
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Grant Theron
Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anna Okunola, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Stellenbosch
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stellenbosch University
Cape Town, Western Cape, South Africa
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Tanzania
South Africa
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TMA2020CDF-3209
Identifier Type: OTHER
Identifier Source: secondary_id
M22/02/004_Sub StudyM20/06/017
Identifier Type: -
Identifier Source: org_study_id